Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | FPR3 | P25089 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700936 | 1.00 | CNR1 (0.38) | CNR1CNR2TAS1R3TAS1R1AURKA | |
| SCHEMBL3707404 | 0.80 | SMN1; SMN2 (0.34) | CNR2 | |
| SCHEMBL3707409 | 0.80 | SMN1; SMN2 (0.34) | CNR2 | |
| SCHEMBL3696232 | 0.78 | CNR2 (0.34) | CNR1CNR2TAS1R3TAS1R1AURKA | |
| SCHEMBL3696231 | 0.78 | CNR2 (0.34) | CNR1CNR2TAS1R3TAS1R1AURKA | |
| SCHEMBL3700934 | 0.73 | NPSR1 (0.37) | CNR1CNR2TAS1R3TAS1R1AAK1 | |
| SCHEMBL3700930 | 0.73 | NPSR1 (0.37) | CNR1CNR2TAS1R3TAS1R1AAK1 | |
| SCHEMBL3694144 | 0.71 | OPRK1 (0.37) | CNR2 | |
| SCHEMBL3694141 | 0.71 | OPRK1 (0.37) | CNR2 | |
| SCHEMBL2704088 | 0.69 | TAS1R3 (0.51) | CNR1CNR2TAS1R3TAS1R1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569484-B2 | Heterocyclic urea derivatives and methods of use thereof | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-20120122817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | UROD, UMPS, SLC14A1 | CNR1 1453/4885CNR2 1386/4885TAS1R3 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.